Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan-Reference-Cited by-同舟云学术

Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan

Published:2020-01-09 Issue:5 Volume:25 Page:912-920
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Narita Shintaro^ORCID,Hatakeyama Shingo,Takahashi Masahiro,Sakurai Toshihiko,Kawamura Sadafumi,Hoshi Senji,Ishida Masanori,Kawaguchi Toshiaki,Ishidoya Shigeto,Shimoda Jiro,Sato Hiromi,Koizumi Atsushi,Mitsuzuka Koji,Tochigi Tatsuo,Tsuchiya Norihiko,Ohyama Chikara,Arai Yoichi,Nomura Kyoko,Habuchi Tomonori

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-019-01614-8.pdf

Reference27 articles.

1. Ferlay J, Colombet M, Soerjomataram I et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144(8):1941–1953. https://doi.org/10.1002/ijc.31937

2. Tsao CK, Oh WK (2018) First line treatment of hormone sensitive metastatic prostate cancer is there a single standard of care? J Clin Oncol 8:9–10. https://doi.org/10.1200/jco.2017.77.4315

3. Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737–746. https://doi.org/10.1056/NEJMoa1503747

4. Barata PC, Sartor AO (2019) Metastatic castration-sensitive prostate cancer: abiraterone, docetaxel, or. Cancer 125(11):1777–1788. https://doi.org/10.1002/cncr.32039

5. Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352–360. https://doi.org/10.1056/NEJMoa1704174

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors;Clinical Genitourinary Cancer;2024-10

2. A retrospective study of prognostic factors and prostate-specific antigen dynamics in Japanese patients with metastatic hormone-sensitive prostate cancer who received combined androgen blockade therapy with bicalutamide;International Journal of Clinical Oncology;2024-08-17

3. Outcomes in studies regarding older patients with prostate cancer: A systematic review;Journal of Geriatric Oncology;2024-06

4. Psoas mass index at the level of the third lumbar vertebra on computed tomography is a prognostic predictor for metastatic castration-sensitive prostate cancer;International Journal of Clinical Oncology;2024-04-08

5. Pretreatment Lymphocyte to C-Reactive Protein Ratio: An Independent Predictor of Overall Survival in Metastatic Hormone-Naïve Prostate Cancer Patients;Clinical Genitourinary Cancer;2023-12